S&P Dow Jones Indices Announces March 2014 Quarterly Rebalance of the S&P/ASX Indices; GI Dynamics to be Included in All Ordinaries Index
GI Dynamics to Present at Cowen & Company 34th Annual Health Care Conference
GI Dynamics Announces Expanded Reimbursement Coverage in Germany
EndoBarrier® is indicated to treat patients with type 2 diabetes and/or obesity for 12 months.
EndoBarrier® has received regulatory approval and is commercially available for use in select international markets.
EndoBarrier® is not approved for sale in the United States and is considered investigational.
CAUTION: INVESTIGATIONAL DEVICE, LIMITED BY FEDERAL (UNITED STATES) LAW TO INVESTIGATIONAL USE